
ChromaDex Corp (NAGE) Stock Forecast & Price Target
ChromaDex Corp (NAGE) Analyst Ratings
Bulls say
Niagen Bioscience is currently a leader in NAD+ science and healthy-aging research, with a strong portfolio of patented molecules and a unique platform focused on boosting NAD+ levels. The launch of their clinician-directed telehealth platform and the recent sale of their Analytical Standards & References business fortify their position in the market. Additionally, a potential favorable outcome for their lawsuit against the FDA and the potential for expansion into new retail channels provide significant growth opportunities for the company. With a strong financial outlook, including projected revenue growth of 10-15%, gross margins of 63.5%, and potential for increased earnings and profits, Niagen Bioscience presents an attractive risk/reward opportunity for investors.
Bears say
Niagen Bioscience is at risk due to the highly competitive nature of the health and wellness market, potential changes in consumer preferences, and the reliance on one key product. Regulatory and stock dilution risks could also negatively impact the company's financials and potential for growth, especially given the recent failed study for Parkinson's. These factors, along with a discount rate of 12.5% and high market entry probability, lead to a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of ChromaDex Corp and is not a guaranteed prediction by Public.com or investment advice.
ChromaDex Corp (NAGE) Analyst Forecast & Price Prediction
Start investing in ChromaDex Corp (NAGE)
Order type
Buy in
Order amount
Est. shares
0 shares